Modality
Cell Therapy
MOA
VEGFi
Target
CD3
Pathway
T-cell
Ovarian CaAtopic DermMM
Development Pipeline
Preclinical
~Jun 2011
→ ~Sep 2012
Phase 1
~Dec 2012
→ ~Mar 2014
Phase 2
~Jun 2014
→ ~Sep 2015
Phase 3
~Dec 2015
→ ~Mar 2017
NDA/BLA
~Jun 2017
→ ~Sep 2018
Approved
Dec 2018
→ Dec 2030
ApprovedCurrent
NCT05330195
1,681 pts·Ovarian Ca
2021-03→2030-10·Completed
NCT05545134
441 pts·Atopic Derm
2018-12→2029-06·Not yet recruiting
NCT08250285
1,222 pts·MM
2020-04→2030-12·Terminated
3,344 total pts3 indications
CompletedCurrentUpcoming
Catalysts (3)
2029-06-213.2y awayPh3 Readout· Atopic Derm
2030-10-144.5y awayPh3 Readout· Ovarian Ca
2030-12-254.7y awayPh3 Readout· MM
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Not yet…
Approved
Termina…
Approved
Complet…
Catalysts
Ph3 Readout
2029-06-21 · 3.2y away
Atopic Derm
Ph3 Readout
2030-10-14 · 4.5y away
Ovarian Ca
Ph3 Readout
2030-12-25 · 4.7y away
MM
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05330195 | Approved | Ovarian Ca | Completed | 1681 | SeizFreq |
| NCT05545134 | Approved | Atopic Derm | Not yet recr... | 441 | SeizFreq |
| NCT08250285 | Approved | MM | Terminated | 1222 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 |